Search Results - "Marschner, N"

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia by Steinmetz, T., Tschechne, B., Harlin, O., Klement, B., Franzem, M., Wamhoff, J., Tesch, H., Rohrberg, R., Marschner, N.

“…Intravenous (i.v.) iron can improve anaemia of chronic disease and response to erythropoiesis-stimulating agents (ESAs), but data on its use in practice and…”
Get full text

Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL by Thill, M., Zahn, M.-O., Welt, A., Stickeler, E., Nusch, A., Fietz, T., Rauh, J., Wetzel, N., Kruggel, L., Jänicke, M., Marschner, N., Harbeck, N., Wöckel, A., Decker, T.

“…Purpose Evidence about routine treatment and outcome of patients with invasive lobular cancer (ILC) is limited, especially regarding metastatic disease. Here…”
Get full text

Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study by Welt, A., Welslau, M.K., Lüftner, D., Deryal, M., Liersch, R., Sahlmann, J., Houet, L., Vannier, C., Marschner, N., Potthoff, K.

Get full text

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer by Schmidt, M., Scheulen, M.E., Dittrich, C., Obrist, P., Marschner, N., Dirix, L., Schmidt, M., Rüttinger, D., Schuler, M., Reinhardt, C., Awada, A.

“…High-level expression of epithelial cell adhesion molecule (EpCAM) is associated with unfavorable prognosis in breast cancer. This study was designed to…”
Get full text

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer by Vrdoljak, E., Marschner, N., Zielinski, C., Gligorov, J., Cortes, J., Puglisi, F., Aapro, M., Fallowfield, L., Fontana, A., Inbar, M., Kahan, Z., Welt, A., Lévy, C., Brain, E., Pivot, X., Putzu, C., González Martín, A., de Ducla, S., Easton, V., von Minckwitz, G.

“…The randomised phase III TANIA trial demonstrated that continuing bevacizumab with second-line chemotherapy for locally recurrent/metastatic breast cancer…”
Get full text

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial by Scheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W. I., Burris, H. A., Cassidy, J., Jodrell, D., Koralewski, P., Levine, E. L., Marschner, N., Maroun, J., Garcia-Alfonso, P., Tujakowski, J., Van Hazel, G., Wong, A., Zaluski, J., Twelves, C.

“…Background: Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil–leucovorin (5-FU/LV) as…”
Get full text

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial by Quidde, J., Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C.A., Killing, B., Depenbusch, R., Steffens, C.-C., Lange, T., Dietrich, G., Stoehlmacher, J., Reinacher, A., Tannapfel, A., Trarbach, T., Marschner, N., Schmoll, H.-J., Hinke, A., Al-Batran, S.-E., Arnold, D.

“…The unique analysis, the first preplanned HRQOL analysis of the phase III AIO KRK 0207 trial, demonstrates that continuation of active maintenance treatment…”
Get full text

Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS) by Marschner, N., Frank, M., Vach, W., Ladda, E., Karcher, A., Winter, S., Jänicke, M., Trarbach, T.

“…Aim Published prognostic scores for metastatic colorectal cancer (mCRC) are based on data from highly selected patient subgroups with specified first‐line…”
Get full text

Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial by Welt, A., Marschner, N., Lerchenmueller, C., Decker, T., Steffens, C.-C., Koehler, A., Depenbusch, R., Busies, S., Hegewisch-Becker, S.

“…The study was designed to evaluate efficacy and superiority of capecitabine/bevacizumab + vinorelbine (CAP/BEV/VIN) compared to CAP/BEV alone. Main purpose was…”
Get full text

Palbociclib in combination with letrozole as first or later line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study by Welslau, M.K., Zaiss, M., Söling, U., Untch, M., Müller, L., Lüftner, D., Meiler, J., Welt, A., Sahlmann, J., Houet, L., Runkel, E., Marschner, N.W.

Get full text

Exploratory biomarker analysis in patients treated with vinorelbine plus everolimus or vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer: Final results from the randomized phase II trial VicTORia by Decker, T., Mündlein, A., Marschner, N., Welt, A., Riedt, T., Hagen, V., Rauh, J., Klein, D., Potthoff, K., Jähnig, P., Schröder, H., Hegewisch-Becker, S., Lerchenmüller, C.

Get full text

Dental management before radiotherapy of the head and neck region: 4‐year single‐center experience by Hoffmann, Lea, Marschner, Sebastian N., Kakoschke, Tamara K., Hickel, Reinhard, Sabbagh, Hisham, Wölfle, Uta C.

“…Objective To review our experience with a standardized dental management approach in patients with planned radiotherapy of the head and neck region based on…”
Get full text

Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases by Ugurluer, Gamze, Schneiders, Famke L., Corradini, Stefanie, Boldrini, Luca, Kotecha, Rupesh, Kelly, Patrick, Portelance, Lorraine, Camilleri, Philip, Ben-David, Merav A., Poiset, Spencer, Marschner, Sebastian N., Panza, Giulia, Kutuk, Tugce, Palacios, Miguel A., Castelluccia, Alessandra, Zoto Mustafayev, Teuta, Atalar, Banu, Senan, Suresh, Ozyar, Enis

“…•MRgSBRT revealed a 2- year LPFS rate of 88%.•Tumors treated with PTV CI of ≥ 0.90 had an improved LPFS.•No local recurrences were observed after a total dose…”
Get full text

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial by Karthaus, M., Kretzschmar, A., Kröning, H., Biakhov, M., Irwin, D., Marschner, N., Slabber, C., Fountzilas, G., Garin, A., Abecasis, N.G.F., Baronius, W., Steger, G.G., Südhoff, T., Giorgetti, C., Reichardt, P.

“…Background: Cancer patients receiving chemotherapy experience thromboembolic complications associated with the use of long-term indwelling central venous…”
Get full text

SANDOZ RITUXIMAB FOR TREATMENT OF DIFFUSE LARGE B‐CELL LYMPHOMA: INTERIM SAFETY RESULTS OF THE NON‐INTERVENTIONAL, OBSERVATIONAL, MULTICENTER, OPEN‐LABEL REFLECT STUDY by Welslau, M., Marschner, N., Wolff, T., Otremba, B., Topaly, J., Bittencourt da Silva, L.

Get full text

Testing for and frequency of molecular alterations in patients with advanced NSCLC in Germany. Results from the prospective German registry CRISP (AIO-TRK-0315) by Griesinger, F., Eberhardt, W.E.E., Nusch, A., Reiser, M., Bernhardt, C., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Weichert, W., Rittmeyer, A., Bischoff, H., Waller, C., Thomas, M.

Get full text

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer by Strumberg, Dirk, Schultheis, Beate, Scheulen, M. E., Hilger, R. A., Krauss, J., Marschner, N., Lordick, F., Bach, F., Reuter, D., Edler, L., Mross, K.

“…Summary Introduction Nimotuzumab is a humanized monoclonal antibody that binds to the EGFR. Based on phase I data, the recommended dose has been established at…”
Get full text

A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: Results from the FAMOUS study by P J, Goebell, A, Münch, L, Müller, H J, Hurtz, M, Koska, S, Busies, N, Marschner

“…Abstract Objective With an increasing choice of new treatment options, the management of side effects to maintain a chosen treatment if likely to be effective…”
Get full text

P1148: REAL WORLD DATA (RWD) AMONG FOLLICULAR LYMPHOMA (FL) PATIENTS IN GERMANY WITH AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY AND COMPARISON WITH CLINICAL DATA FOR MOSUNETUZUMAB by Marschner, N., Hanselmann, J., McGough, S., Braun, S., Pfizler‐Dempfle, S., Sandner, R., Mohm, J., Jaber, M., Hamm, D., Hamm, N., Jaenicke, M., Shewade, A.

Get full text

Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer by Schmidt, M., Rüttinger, D., Sebastian, M., Hanusch, C.A., Marschner, N., Baeuerle, P.A., Wolf, A., Göppel, G., Oruzio, D., Schlimok, G., Steger, G.G., Wolf, C., Eiermann, W., Lang, A., Schuler, M.

“…Targeted therapy options in HER2-negative breast cancer are limited. This open-label, multicenter phase IB dose-escalation trial was conducted to determine…”
Get full text